Adjuvant immunotherapy of dendritic cells and cytokine-induced killer cells is safe and enhances chemotherapy efficacy for multiple myeloma in China: a meta-analysis of clinical trials

The aim of this study was to systematically evaluate the efficacy and safety of the combination of dendritic cells and cytokine-induced killer cells (DC-CIK) adjuvant immunotherapy and chemotherapy in the treatment of multiple myeloma (MM). Clinical trials were gathered by searching Web of Science,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug design, development and therapy development and therapy, 2017, Vol.11, p.3245-3256
Hauptverfasser:	Wang, Yan, Lv, Benji, Li, Ke, Zhang, Anqi, Liu, Hong
Format:	Artikel
Sprache:	eng
Schlagworte:	adjuvant immunotherapy Adjuvants, Immunologic - therapeutic use Antineoplastic Agents - therapeutic use Bone marrow Cancer therapies CD25 antigen CD4 antigen CD8 antigen Chemotherapy China Clinical trials Clinical Trials as Topic Combined Modality Therapy Combined treatment Comparative analysis Complications and side effects Confidence intervals Creatinine cytokine-induced killer cells Cytokine-Induced Killer Cells - immunology Cytokines Dendritic cells Dendritic Cells - immunology Disease control Drug therapy Effectiveness Genetic aspects Hematology Humans Immune response Immunotherapy Interleukin 10 Interleukin 12 Interleukin 2 Interleukin 4 Interleukin 6 Killer cells Laboratories Light chains Lymphocytes Lymphoma M protein Medical prognosis Medical research Meta-analysis Metastasis Multiple myeloma Multiple Myeloma - drug therapy Original Research Patients Physiological aspects Prognosis Quality of life Statistical analysis Transplants & implants Tumor cells Urine γ-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of this study was to systematically evaluate the efficacy and safety of the combination of dendritic cells and cytokine-induced killer cells (DC-CIK) adjuvant immunotherapy and chemotherapy in the treatment of multiple myeloma (MM). Clinical trials were gathered by searching Web of Science, PubMed, Embase, Cochrane Library, Wanfang, and CNKI database. Outcome measurements including therapeutic efficacy, prognosis, immune function, and adverse events were extracted and evaluated. A total of 12 trials including 594 MM patients were involved in this study for statistical analysis. Results indicated that compared to chemotherapy alone, the combination of DC-CIK immunotherapy with chemotherapy significantly improved patients' overall response rate (ORR, odds ratio [OR] =2.77, 95% confidence interval [CI] =1.88-4.10,
ISSN:	1177-8881 1177-8881
DOI:	10.2147/DDDT.S146959